金域医学连跌7天，华宝基金旗下1只基金位列前十大股东

Core Viewpoint - Guangzhou Kingmed Diagnostics Group Co., Ltd. has experienced a decline in stock price, with a cumulative drop of -10.12% over the past seven trading days, indicating potential challenges in the market [1] Company Overview - Kingmed Diagnostics focuses on third-party medical testing and pathology diagnosis, leveraging core resources such as "large platforms, networks, services, samples, and data" to provide advanced medical diagnostic information integration services to healthcare institutions across China [1] Financial Performance - The financial report indicates that Huabao Fund's Huabao CSI Medical ETF is among the top ten shareholders of Kingmed Diagnostics, having reduced its holdings in the first quarter of this year [1] - Year-to-date performance of the ETF shows a return of -1.01%, ranking 2505 out of 3432 in its category [2] Market Comparison - The ETF's performance over various periods is as follows: - Recent week: -0.25% - Recent month: +3.42% - Recent three months: -11.01% - Recent six months: -3.41% - Year-to-date: -1.01% - Comparatively, the average performance of similar funds shows a year-to-date return of +2.62% [2] Fund Management - The fund manager, Hu Jie, has extensive experience in the financial sector, having joined Huabao Fund in June 2006 and currently serving as the Director of Index Investment [4][5] - Hu Jie has managed multiple funds over her career, including the Huabao CSI Medical Index Fund and others, demonstrating a strong track record in fund management [5]